We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+21.88%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$2.74B
AUM Growth
+$366M
Cap. Flow
+$279M
Cap. Flow %
10.2%
Top 10 Hldgs %
49.25%
Holding
82
New
4
Increased
18
Reduced
6
Closed
10

Top Buys

Rank Stock Value
1
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$84.9M
2
PTGX icon
Protagonist Therapeutics
PTGX
+$63.4M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$54M
4
RVMD icon
Revolution Medicines
RVMD
+$41.9M
5
GPCR icon
Structure Therapeutics
GPCR
+$41.1M

Top Sells

Rank Stock Value
1
RCUS icon
Arcus Biosciences
RCUS
+$47.6M
2
CGEM icon
Cullinan Oncology
CGEM
+$47.5M
3
VRDN icon
Viridian Therapeutics
VRDN
+$34.3M
4
CNCE
Concert Pharmaceuticals, Inc.
CNCE
+$21.2M
5
ANNX icon
Annexon
ANNX
+$19.5M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MLTX icon
1
MoonLake Immunotherapeutics
MLTX
$1.59B
$465M 17.01%
21,751,284
– –
KYMR icon
2
Kymera Therapeutics
KYMR
$8.6B
$140M 5.13%
4,739,004
+46,400
+1% +$1.5M
AXSM icon
3
Axsome Therapeutics
AXSM
$11.5B
$131M 4.81%
2,131,100
+376,100
+21% +$24.7M
RVMD icon
4
Revolution Medicines
RVMD
$39.9B
$107M 3.92%
4,955,588
+1,700,000
+52% +$41.9M
IONS icon
5
Ionis Pharmaceuticals
IONS
$8.61B
$91.5M 3.35%
2,560,761
+1,438,952
+128% +$54M
PTGX icon
6
Protagonist Therapeutics
PTGX
$8.7B
$86.8M 3.17%
+3,775,900
New +$63.4M
LKFT
7
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.79B
$83.7M 3.06%
2,165,109
+2,065,109
+2,065% +$84.9M
KURA icon
8
Kura Oncology
KURA
$805M
$82.3M 3.01%
6,730,983
+2,930,000
+77% +$36.6M
RPTX
9
DELISTED
Repare Therapeutics
RPTX
$81.6M 2.98%
8,291,988
– –
PNT
10
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$76.8M 2.81%
10,563,748
+1,386,000
+15% +$10.3M
XOMA
11
DELISTED
Xoma
XOMA
$76.7M 2.8%
3,633,743
+22,249
+0.6% +$468K
GHRS icon
12
GH Research
GHRS
$1.95B
$74.1M 2.71%
9,275,158
– –
FDMT icon
13
4D Molecular Therapeutics
FDMT
$539M
$68.9M 2.52%
4,007,413
– –
XENE icon
14
Xenon Pharmaceuticals
XENE
$6.13B
$65.4M 2.39%
1,827,958
+556,715
+44% +$20.6M
MRUS
15
DELISTED
Merus
MRUS
$54.8M 2%
2,978,420
– –
ZYME icon
16
Zymeworks
ZYME
$1.63B
$53.1M 1.94%
5,870,000
– –
TYRA icon
17
Tyra Biosciences
TYRA
$1.92B
$52.1M 1.9%
3,239,595
+767,268
+31% +$9.13M
RLAY icon
18
Relay Therapeutics
RLAY
$4.12B
$51.4M 1.88%
3,120,521
-755,500
-19% -$13.5M
SNDX icon
19
Syndax Pharmaceuticals
SNDX
$1.69B
$45.3M 1.65%
2,143,197
+692,000
+48% +$17.2M
CRNX icon
20
Crinetics Pharmaceuticals
CRNX
$8.87B
$44M 1.61%
2,736,613
– –
GPCR icon
21
Structure Therapeutics
GPCR
$3.38B
$41.6M 1.52%
+1,750,000
New +$41.1M
IMVT icon
22
Immunovant
IMVT
$7.92B
$39.7M 1.45%
2,561,000
– –
LXRX icon
23
Lexicon Pharmaceuticals
LXRX
$1.03B
$39.2M 1.43%
16,149,179
– –
REPL icon
24
Replimune Group
REPL
$915M
$37.8M 1.38%
2,143,036
+620,407
+41% +$14.8M
CTIC
25
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$37M 1.35%
8,813,021
– –
1
2 3 4

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q1 2023 Portfolio in Review

As of Q1 2023, BVF Inc held 82 positions worth $2.74B, up 15% from $2.37B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

BVF Inc deployed $279M of net new capital in Q1 2023, opening 4 new positions and adding to 18 existing holdings. Its largest new stake was Protagonist Therapeutics: 3,775,900 shares worth $86.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

On the sell side, the largest reduction was Cullinan Oncology, an estimated $47.5M trimmed.

  • BVF Inc's largest Q1 2023 buy was Protagonist Therapeutics: 3,775,900 shares worth $86.8M.
  • BVF Inc added most to Lakefront Biotherapeutics American Depositary Shares in Q1 2023, an estimated $84.9M increase.
  • BVF Inc's biggest Q1 2023 reduction was Cullinan Oncology, cutting an estimated $47.5M.
  • BVF Inc fully exited Arcus Biosciences in Q1 2023, selling an estimated $47.6M.
  • BVF Inc's ten largest holdings make up 49% of its $2.74B portfolio in Q1 2023.
  • BVF Inc opened 4 new positions and closed 10 in Q1 2023.
  • BVF Inc's portfolio value rose 15% quarter-over-quarter to $2.74B.

Based on BVF Inc's 13F filing for Q1 2023, filed 15 May 2023.